The pharmaceutical company Sarepta Therapeutics Inc.has created a medication named eteplirsen (also known as AVI-4658). It is designed for treatment of some mutations which cause Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease. This treatment could allow for victims of DMD to be active for longer periods, and prevent deterioration for longer.
There is currently no cure for DMD, and treatment methods to minimize symptoms would be greatly helped by this medication.
Please encourage the FDA to utilize the Fast Track process to consider approving Eteplirsen.